Catherine Fuchs

Catherine Fuchs

Auto-generated profile, based on publicly available information

Catherine Fuchs

Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences Vanderbilt University Medical Center at Village of Vanderbilt Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2025 in Autism Research
Verified
Journal Article
Open access
JSJoshua Ryan Smith
Joshua Ryan Smith
SLSeri Lim
Seri Lim
SBSnehal Bindra
Snehal Bindra
SMSarah Marler
Sarah Marler
BRBavani Rajah
Bavani Rajah
JLJames Luccarelli
James Luccarelli
Catatonia is a highly morbid psychomotor and affective disorder, which can affect autistic individuals with and without intellectual disability. Catatonic symptoms are treatable with pharmacotherapy and electroconvulsive therapy, but the longitudinal effectiveness of these treatments in autistic individuals has not been described. We conducted a prospective observational cohort study of patients with autism and co‐morbid catatonia who received outpatient care in a specialized outpatient clinic from July 1, 2021 to May 31, 2024. Data investigating pharmacologic interventions, and clinical measures including the Bush Francis Catatonia Rating Scale (BFCRS), Kanner Catatonia Severity Scale (KCS), Kanner Catatonia Examination (KCE), and Clinical Global Impression—Improvement (CGI‐I) were collected. Forty‐five autistic patients with co‐morbid catatonia were treated during the study period. The mean age was 15.6 (SD = 7.9) years [Mdn = 16.0, range 6.0–31.0]. Forty‐one patients (91.1%) met criteria for autism with co‐occurring intellectual disability. All patients received pharmacotherapy. Forty‐four (97.8%) were treated with benzodiazepines with a mean maximal daily dose of 17.4 mg (SD = 15.8) lorazepam equivalents. Thirty‐five patients (77.8%) required more than one medication class for treatment. Sixteen (35.6%) patients received electroconvulsive therapy. Fourteen patients (31.1%) attempted to taper off benzodiazepines after achieving clinical improvement during the study period; of these, 5 patients (11.1%) were successfully tapered off, and the remaining 9 (17.8%) discontinued the taper due to a return of catatonic symptoms. Statistically significant improvement was observed across all clinical domains except the KCS. However, the majority remained at least partially symptomatic over the study period. Three patients (6.7%) died over the study period. Despite clinical improvements while receiving the gold standard for psychopharmacologic management of catatonia, chronic symptoms remained for the majority of catatonia patients over the study period, and few were able to taper and discontinue benzodiazepine treatment. Notably, the open label design of this study is a limiting factor when interpreting the results.

5 September 2024 in Journal of the Academy of Consultation-Liaison Psychiatry
Verified
Journal Article
Closed access
JSJoshua Ryan Smith
Joshua Ryan Smith
TYTasia York
Tasia York
SHSarah Hart
Sarah Hart
APAnuj Patel
Anuj Patel
HKHeather L. Kreth
Heather L. Kreth
CFCatherine Fuchs
Catherine Fuchs

23 August 2023 in Journal of the Academy of Consultation-Liaison Psychiatry
Verified
Journal Article
Closed access
THTucker Hickox
Tucker Hickox
KBKhyati Brahmbhatt
Khyati Brahmbhatt
JSJoshua R. Smith
Joshua R. Smith
CFCatherine Fuchs
Catherine Fuchs
YTYasas Tanguturi
Yasas Tanguturi

1 January 2020 in Psychosomatics
Verified
Journal Article
Closed access
KSKiera Schlansky
Kiera Schlansky
BFBenjin Facer
Benjin Facer
YTYasas C. Tanguturi
Yasas C. Tanguturi
ACAllyson Witters Cundiff
Allyson Witters Cundiff
DFD. Catherine Fuchs
D. Catherine Fuchs

1 February 2024 in Neurology Clinical Practice
Verified
Journal Article
Closed access
KBKelsey M. Barter
Kelsey M. Barter
CFCatherine Fuchs
Catherine Fuchs
TGThomas B. Graham
Thomas B. Graham
LPLindsay M. Pagano
Lindsay M. Pagano
MVMcKenzie Vater
McKenzie Vater
A clinical practice guideline (CPG) was created to standardize evaluation and treatment for patients with suspected anti-methyl-d-aspartate receptor (NMDAR) autoimmune encephalitis (AE), the most common AE in children. The objective of this study was to evaluate the CPG effect on time to diagnosis, treatment, and hospital length of stay (LOS). Patients with an inpatient consult to pediatric rheumatology for AE during a 4-year period (period 2) after CPG implementation were identified. Data were extracted and compared with data over the preceding 4-year period (period 1). During period 1, fewer patients underwent diagnostic testing than during period 2 (34 vs 80). Number of patients diagnosed with AE did not differ from period 1 to that from period 2 (NMDAR AE 9 vs 8; seronegative AE 4 vs 5). The average time to diagnostic evaluation with lumbar puncture decreased from 5.4 to 1.5 days (p = 0.0082), and time to treatment decreased from 7.6 to 3.9 days (p = 0.018). LOS showed a trend toward improvement (40.4-29.2 days (p = 0.23)). Creation of a CPG for patients with suspected AE was associated with an improved time to diagnostic evaluation and treatment. With the CPG, more patients underwent AE testing, though total diagnoses remained the same.

1 November 2021 in Hospital Pediatrics
Verified
Journal Article
Closed access
PDF file
YTYasas C. Tanguturi
Yasas C. Tanguturi
EHEmily Hanzlik
Emily Hanzlik
LPLindsay Pagano
Lindsay Pagano
ACAllyson Witters Cundiff
Allyson Witters Cundiff
TGThomas Brent Graham
Thomas Brent Graham
DFD. Catherine Fuchs
D. Catherine Fuchs